Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-06-01
DOI
10.1007/s00259-023-06272-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 177Lu-FAPI Therapy in a Patient With End-Stage Metastatic Pancreatic Adenocarcinoma
- (2022) Fatemeh Kaghazchi et al. CLINICAL NUCLEAR MEDICINE
- 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention
- (2022) Hongsheng Li et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
- (2022) Dirk Zboralski et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
- (2022) Muhsin H. Younis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
- (2022) Andrea Galbiati et al. JOURNAL OF NUCLEAR MEDICINE
- Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine
- (2022) Circe D. van der Heide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy
- (2022) Liang Zhao et al. MOLECULAR PHARMACEUTICS
- Fibroblast activation protein targeted radioligand therapy for treatment of solid tumors
- (2022) Spencer Dirk Lindeman et al. JOURNAL OF NUCLEAR MEDICINE
- [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
- (2021) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
- (2021) Jacopo Millul et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers
- (2021) Majid Assadi et al. CLINICAL NUCLEAR MEDICINE
- Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of 68Ga-labeled FAPI dimer
- (2021) Liang Zhao et al. JOURNAL OF NUCLEAR MEDICINE
- Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results
- (2021) Richard P Baum et al. JOURNAL OF NUCLEAR MEDICINE
- Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy
- (2021) Pu Zhang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- (2021) Mengxin Xu et al. JOURNAL OF NUCLEAR MEDICINE
- Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics
- (2021) Xuejun Wen et al. Theranostics
- First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2
- (2021) Sanjana Ballal et al. Pharmaceuticals
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- (2020) Jeremie Calais JOURNAL OF NUCLEAR MEDICINE
- The role of fibroblast activation protein in health and malignancy
- (2020) Allison A. Fitzgerald et al. CANCER AND METASTASIS REVIEWS
- High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes
- (2020) Mairene Coto-Llerena et al. Frontiers in Oncology
- Development of novel FAP-targeted radiotracers with improved tumor retention
- (2019) Anastasia Loktev et al. JOURNAL OF NUCLEAR MEDICINE
- FAPI-PET/CT: Mean intensity of tracer-uptake (SUV) in 28 different kinds of cancer
- (2019) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients
- (2019) Catherine Meyer et al. JOURNAL OF NUCLEAR MEDICINE
- Evidence for an effect of receptor density on ligand occupancy and agonist EC50
- (2019) Gavin E. Jarvis et al. Scientific Reports
- Biodistribution, Pharmacokinetics, and Dosimetry of 177 Lu-, 90 Y-, and 111 In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177 Lu-DOTATATE: The Mass Effect
- (2017) Guillaume P. Nicolas et al. JOURNAL OF NUCLEAR MEDICINE
- Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts
- (2016) Alessandro Arcucci et al. Biomed Research International
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search